|View printer-friendly version|
AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer
that has been shown to improve disease indices in multiple models of
inflammatory bowel disease (IBD). “Unlike other HIF stabilizers that
mainly affect HIF-2 and stimulate erythropoiesis, AKB-4924 is unique in
that it preferentially stabilizes HIF-1 alpha, which has a profound
anti-inflammatory and mucosal healing effect. These properties make it
an ideal candidate for the treatment of IBD,” said
The aim of the current study is to evaluate the safety and tolerability of multiple daily doses of AKB-4924 in healthy volunteers. The single-center pharmacokinetic and safety study is expected to enroll 24 subjects into 3 dose cohorts, randomized 3:1 to receive either AKB-4924 or placebo orally once daily for 8 days.
AKB-4924, a selective stabilizer of HIF-1 alpha, is being developed for the treatment of IBD. HIF-1 alpha is involved in mucosal wound healing and the reduction of inflammation in the gastrointestinal tract. We have completed a single ascending dose clinical trial of AKB-4924 in healthy volunteers to date.
Forward Looking Statements
This press release contains forward-looking statements. Statements in
this press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things,
the timeline of, and other developmental plans for, AKB-4924 for
inflammatory bowel disease or otherwise, the therapeutic
potential of the Company’s product candidates, including AKB-4924, and
the Company’s financial position. Actual results could differ from those
projected in any forward-looking statements due to several risk factors.
Such factors include, among others, the ability to raise the additional
funding needed to continue to develop AKB-4924 or other product
development plans, the inherent uncertainties associated with the
Investors & Media:
Aerpio Pharmaceuticals, Inc.
Chief Financial Officer
Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.